Floatz logo

Sti-1386

Hepatic Metastasis

Sorrento Therapeutics, Inc.gene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hepatic Metastasis cohort.

Asset / SponsorPhaseRating
Octreotide Pamoate
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2CCC

Same molecule, other indications

Sti-1386 is also rated in:

malignant pancreatic neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
sarcomaDormant
C
Indicative ·
39 / 100
View asset →
cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →